25 XP   0   0   10

Percheron Therapeutics Limited
Buy, Hold or Sell?

Let's analyse Percheron Therapeutics Limited together

PenkeI guess you are interested in Percheron Therapeutics Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Percheron Therapeutics Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Percheron Therapeutics Limited

I send you an email if I find something interesting about Percheron Therapeutics Limited.

Quick analysis of Percheron Therapeutics Limited (30 sec.)










What can you expect buying and holding a share of Percheron Therapeutics Limited? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
30.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$-0.04
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.05
Return On Investment
-64.3%

For what price can you sell your share?

Current Price per Share
A$0.08
Expected price per share
A$0.075 - A$0.11
How sure are you?
50%

1. Valuation of Percheron Therapeutics Limited (5 min.)




Live pricePrice per Share (EOD)

A$0.08

Intrinsic Value Per Share

A$-0.12 - A$-0.06

Total Value Per Share

A$-0.11 - A$-0.05

2. Growth of Percheron Therapeutics Limited (5 min.)




Is Percheron Therapeutics Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$6.4m$13.6m-$7.2m-111.9%

How much money is Percheron Therapeutics Limited making?

Current yearPrevious yearGrowGrow %
Making money-$7.3m-$3.7m-$3.5m-48.7%
Net Profit Margin-2,956.4%-17,068.7%--

How much money comes from the company's main activities?

3. Financial Health of Percheron Therapeutics Limited (5 min.)




What can you expect buying and holding a share of Percheron Therapeutics Limited? (5 min.)

Welcome investor! Percheron Therapeutics Limited's management wants to use your money to grow the business. In return you get a share of Percheron Therapeutics Limited.

What can you expect buying and holding a share of Percheron Therapeutics Limited?

First you should know what it really means to hold a share of Percheron Therapeutics Limited. And how you can make/lose money.

Speculation

The Price per Share of Percheron Therapeutics Limited is A$0.077. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Percheron Therapeutics Limited.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Percheron Therapeutics Limited, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$-0.01 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Percheron Therapeutics Limited.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-10.6%-0.01-10.6%0.00-5.4%0.00-6.4%0.00-4.1%
Usd Book Value Change Per Share-0.01-10.4%-0.01-10.4%0.0114.4%0.001.1%0.000.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.1%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-10.4%-0.01-10.4%0.0114.4%0.001.1%0.000.5%
Usd Price Per Share0.04-0.04-0.05-0.06-0.05-
Price to Earnings Ratio-4.67--4.67--11.63--12.64-1.00-
Price-to-Total Gains Ratio-4.76--4.76-4.36-29.00-10.39-
Price to Book Ratio5.33-5.33-3.20-13.68-17.10-
Price-to-Total Gains Ratio-4.76--4.76-4.36-29.00-10.39-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0498344
Number of shares20066
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share-0.010.00
Gains per Quarter (20066 shares)-160.8417.33
Gains per Year (20066 shares)-643.3769.31
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-643-65336659
20-1287-12966133128
30-1930-19399199197
40-2573-258212265266
50-3217-322515332335
60-3860-386818398404
70-4504-451121464473
80-5147-515424531542
90-5790-579727597611
100-6434-644030663680

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%1.09.00.010.0%1.022.00.04.3%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%10.013.00.043.5%
Dividend per Share0.00.01.00.0%2.00.01.066.7%3.00.02.060.0%3.00.07.030.0%3.00.020.013.0%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%5.05.00.050.0%10.013.00.043.5%

Fundamentals of Percheron Therapeutics Limited

About Percheron Therapeutics Limited

Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of multiple sclerosis, Duchenne Muscular Dystrophy, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. The company was formerly known as Antisense Therapeutics Limited and changed its name to Percheron Therapeutics Limited in December 2023. The company was incorporated in 2000 and is based in Melbourne, Australia.

Fundamental data was last updated by Penke on 2024-03-31 03:20:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Percheron Therapeutics Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Percheron Therapeutics Limited earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of -2,956.4% means that $-29.56 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Percheron Therapeutics Limited:

  • The MRQ is -2,956.4%. The company is making a huge loss. -2
  • The TTM is -2,956.4%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-2,956.4%TTM-2,956.4%0.0%
TTM-2,956.4%YOY-17,068.7%+14,112.3%
TTM-2,956.4%5Y-47,159.6%+44,203.2%
5Y-47,159.6%10Y-25,277.1%-21,882.5%
1.1.2. Return on Assets

Shows how efficient Percheron Therapeutics Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • -88.6% Return on Assets means that Percheron Therapeutics Limited generated $-0.89 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Percheron Therapeutics Limited:

  • The MRQ is -88.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -88.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-88.6%TTM-88.6%0.0%
TTM-88.6%YOY-26.0%-62.6%
TTM-88.6%5Y-80.4%-8.2%
5Y-80.4%10Y-71.1%-9.4%
1.1.3. Return on Equity

Shows how efficient Percheron Therapeutics Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • -114.1% Return on Equity means Percheron Therapeutics Limited generated $-1.14 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Percheron Therapeutics Limited:

  • The MRQ is -114.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -114.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-114.1%TTM-114.1%0.0%
TTM-114.1%YOY-27.6%-86.5%
TTM-114.1%5Y-98.9%-15.2%
5Y-98.9%10Y-88.8%-10.1%

1.2. Operating Efficiency of Percheron Therapeutics Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Percheron Therapeutics Limited is operating .

  • Measures how much profit Percheron Therapeutics Limited makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of -3,466.9% means the company generated $-34.67  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Percheron Therapeutics Limited:

  • The MRQ is -3,466.9%. The company is operating very inefficient. -2
  • The TTM is -3,466.9%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-3,466.9%TTM-3,466.9%0.0%
TTM-3,466.9%YOY-22,268.1%+18,801.1%
TTM-3,466.9%5Y-52,143.9%+48,676.9%
5Y-52,143.9%10Y-28,106.5%-24,037.3%
1.2.2. Operating Ratio

Measures how efficient Percheron Therapeutics Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 34.67 means that the operating costs are $34.67 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 34.669. The company is inefficient in keeping operating costs low. -1
  • The TTM is 34.669. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ34.669TTM34.6690.000
TTM34.669YOY222.681-188.011
TTM34.6695Y521.855-487.185
5Y521.85510Y282.911+238.944

1.3. Liquidity of Percheron Therapeutics Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Percheron Therapeutics Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 4.51 means the company has $4.51 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 4.513. The company is very able to pay all its short-term debts. +2
  • The TTM is 4.513. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ4.513TTM4.5130.000
TTM4.513YOY19.142-14.629
TTM4.5135Y8.159-3.646
5Y8.15910Y7.766+0.393
1.3.2. Quick Ratio

Measures if Percheron Therapeutics Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 8.22 means the company can pay off $8.22 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 8.223. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 8.223. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ8.223TTM8.2230.000
TTM8.223YOY34.021-25.798
TTM8.2235Y11.703-3.480
5Y11.70310Y9.840+1.863

1.4. Solvency of Percheron Therapeutics Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Percheron Therapeutics Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Percheron Therapeutics Limited to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.22 means that Percheron Therapeutics Limited assets are financed with 22.3% credit (debt) and the remaining percentage (100% - 22.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.223. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.223. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.223TTM0.2230.000
TTM0.223YOY0.058+0.166
TTM0.2235Y0.171+0.052
5Y0.17110Y0.168+0.003
1.4.2. Debt to Equity Ratio

Measures if Percheron Therapeutics Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 28.7% means that company has $0.29 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Percheron Therapeutics Limited:

  • The MRQ is 0.287. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.287. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.287TTM0.2870.000
TTM0.287YOY0.061+0.226
TTM0.2875Y0.214+0.074
5Y0.21410Y0.209+0.004

2. Market Valuation of Percheron Therapeutics Limited

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Percheron Therapeutics Limited generates.

  • Above 15 is considered overpriced but always compare Percheron Therapeutics Limited to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of -4.67 means the investor is paying $-4.67 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Percheron Therapeutics Limited:

  • The EOD is -6.100. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.674. Based on the earnings, the company is expensive. -2
  • The TTM is -4.674. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.100MRQ-4.674-1.426
MRQ-4.674TTM-4.6740.000
TTM-4.674YOY-11.634+6.960
TTM-4.6745Y-12.638+7.963
5Y-12.63810Y1.000-13.638
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Percheron Therapeutics Limited:

  • The EOD is -8.486. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.502. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.502. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-8.486MRQ-6.502-1.984
MRQ-6.502TTM-6.5020.000
TTM-6.502YOY-8.659+2.157
TTM-6.5025Y-803.098+796.596
5Y-803.09810Y-400.798-402.300
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Percheron Therapeutics Limited is to cheap or to expensive compared to its book value.

Let's take a look of the Price to Book Ratio trends of Percheron Therapeutics Limited:

  • The EOD is 6.959. Based on the equity, the company is overpriced. -1
  • The MRQ is 5.332. Based on the equity, the company is overpriced. -1
  • The TTM is 5.332. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.959MRQ5.332+1.627
MRQ5.332TTM5.3320.000
TTM5.332YOY3.198+2.134
TTM5.3325Y13.678-8.345
5Y13.67810Y17.099-3.421
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Percheron Therapeutics Limited.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Percheron Therapeutics Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.012-0.0120%0.017-172%0.001-1070%0.001-2195%
Book Value Per Share--0.0110.0110%0.023-53%0.010+13%0.007+56%
Current Ratio--4.5134.5130%19.142-76%8.159-45%7.766-42%
Debt To Asset Ratio--0.2230.2230%0.058+287%0.171+30%0.168+33%
Debt To Equity Ratio--0.2870.2870%0.061+369%0.214+34%0.209+37%
Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Eps---0.013-0.0130%-0.006-49%-0.008-40%-0.005-61%
Free Cash Flow Per Share---0.009-0.0090%-0.009-5%-0.006-37%-0.004-57%
Free Cash Flow To Equity Per Share---0.009-0.0090%0.015-163%0.002-531%0.001-934%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---0.060--------
Intrinsic Value_10Y_min---0.117--------
Intrinsic Value_1Y_max---0.004--------
Intrinsic Value_1Y_min---0.009--------
Intrinsic Value_3Y_max---0.014--------
Intrinsic Value_3Y_min---0.030--------
Intrinsic Value_5Y_max---0.026--------
Intrinsic Value_5Y_min---0.053--------
Market Cap69418966.848+23%53191156.41653191156.4160%67615876.800-21%80778434.150-34%71402365.901-26%
Net Profit Margin---29.564-29.5640%-170.687+477%-471.596+1495%-252.771+755%
Operating Margin---34.669-34.6690%-222.681+542%-521.439+1404%-281.065+711%
Operating Ratio--34.66934.6690%222.681-84%521.855-93%282.911-88%
Pb Ratio6.959+23%5.3325.3320%3.198+67%13.678-61%17.099-69%
Pe Ratio-6.100-31%-4.674-4.6740%-11.634+149%-12.638+170%1.000-567%
Price Per Share0.077+23%0.0590.0590%0.075-21%0.090-34%0.079-26%
Price To Free Cash Flow Ratio-8.486-31%-6.502-6.5020%-8.659+33%-803.098+12251%-400.798+6064%
Price To Total Gains Ratio-6.217-31%-4.764-4.7640%4.364-209%28.998-116%10.389-146%
Quick Ratio--8.2238.2230%34.021-76%11.703-30%9.840-16%
Return On Assets---0.886-0.8860%-0.260-71%-0.804-9%-0.711-20%
Return On Equity---1.141-1.1410%-0.276-76%-0.989-13%-0.888-22%
Total Gains Per Share---0.012-0.0120%0.017-172%0.001-1028%0.001-2098%
Usd Book Value--6456250.3886456250.3880%13682739.321-53%5719347.432+13%4143093.192+56%
Usd Book Value Change Per Share---0.008-0.0080%0.011-172%0.001-1070%0.000-2195%
Usd Book Value Per Share--0.0070.0070%0.015-53%0.006+13%0.005+56%
Usd Dividend Per Share----0%0.000-100%0.000-100%0.000-100%
Usd Eps---0.008-0.0080%-0.004-49%-0.005-40%-0.003-61%
Usd Free Cash Flow---5294497.264-5294497.2640%-5054035.929-5%-3339304.252-37%-2259257.992-57%
Usd Free Cash Flow Per Share---0.006-0.0060%-0.006-5%-0.004-37%-0.003-57%
Usd Free Cash Flow To Equity Per Share---0.006-0.0060%0.009-163%0.001-531%0.001-934%
Usd Market Cap44927955.344+23%34425316.43234425316.4320%43760995.465-21%52279802.582-34%46211611.211-26%
Usd Price Per Share0.050+23%0.0380.0380%0.049-21%0.058-34%0.051-26%
Usd Profit---7365024.682-7365024.6820%-3775816.576-49%-4333285.144-41%-2807798.436-62%
Usd Revenue--249120.224249120.2240%22121.296+1026%67306.211+270%359948.888-31%
Usd Total Gains Per Share---0.008-0.0080%0.011-172%0.001-1028%0.000-2098%
 EOD+5 -3MRQTTM+0 -0YOY+5 -305Y+9 -2610Y+9 -26

4.2. Fundamental Score

Let's check the fundamental score of Percheron Therapeutics Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.100
Price to Book Ratio (EOD)Between0-16.959
Net Profit Margin (MRQ)Greater than0-29.564
Operating Margin (MRQ)Greater than0-34.669
Quick Ratio (MRQ)Greater than18.223
Current Ratio (MRQ)Greater than14.513
Debt to Asset Ratio (MRQ)Less than10.223
Debt to Equity Ratio (MRQ)Less than10.287
Return on Equity (MRQ)Greater than0.15-1.141
Return on Assets (MRQ)Greater than0.05-0.886
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Percheron Therapeutics Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5042.071
Ma 20Greater thanMa 500.085
Ma 50Greater thanMa 1000.081
Ma 100Greater thanMa 2000.069
OpenGreater thanClose0.078
Total4/5 (80.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets12,843
Total Liabilities2,867
Total Stockholder Equity9,976
 As reported
Total Liabilities 2,867
Total Stockholder Equity+ 9,976
Total Assets = 12,843

Assets

Total Assets12,843
Total Current Assets12,692
Long-term Assets151
Total Current Assets
Cash And Cash Equivalents 10,967
Short-term Investments 10,500
Net Receivables 1,659
Inventory 0
Total Current Assets  (as reported)12,692
Total Current Assets  (calculated)23,126
+/- 10,434
Long-term Assets
Property Plant Equipment 151
Long-term Assets  (as reported)151
Long-term Assets  (calculated)151
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,812
Long-term Liabilities55
Total Stockholder Equity9,976
Total Current Liabilities
Short-term Debt 94
Accounts payable 1,023
Other Current Liabilities 1,789
Total Current Liabilities  (as reported)2,812
Total Current Liabilities  (calculated)2,906
+/- 94
Long-term Liabilities
Long term Debt Total 48
Other Liabilities 7
Long-term Liabilities  (as reported)55
Long-term Liabilities  (calculated)55
+/- 0
Total Stockholder Equity
Common Stock98,263
Retained Earnings -92,289
Other Stockholders Equity 4,002
Total Stockholder Equity (as reported)9,976
Total Stockholder Equity (calculated)9,976
+/-0
Other
Capital Stock98,263
Cash and Short Term Investments 10,967
Common Stock Shares Outstanding 634,294
Current Deferred Revenue-94
Liabilities and Stockholders Equity 12,843
Net Debt -10,825
Net Invested Capital 9,976
Net Tangible Assets 9,976
Net Working Capital 9,880
Property Plant and Equipment Gross 735
Short Long Term Debt Total 142



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-30
> Total Assets 
20,088
15,334
11,982
18,151
11,222
9,116
8,050
9,866
4,989
1,816
2,436
5,689
5,201
2,656
7,673
5,327
2,539
4,802
3,699
5,352
7,001
22,437
12,843
12,84322,4377,0015,3523,6994,8022,5395,3277,6732,6565,2015,6892,4361,8164,9899,8668,0509,11611,22218,15111,98215,33420,088
   > Total Current Assets 
13,686
9,566
7,493
14,943
9,301
8,649
8,032
9,852
4,981
1,801
2,428
5,674
5,188
2,642
7,668
5,324
2,525
4,794
3,696
5,214
6,699
22,220
12,692
12,69222,2206,6995,2143,6964,7942,5255,3247,6682,6425,1885,6742,4281,8014,9819,8528,0328,6499,30114,9437,4939,56613,686
       Cash And Cash Equivalents 
13,675
9,373
6,546
14,421
8,821
8,239
7,597
6,362
3,076
1,726
2,338
4,968
4,000
1,335
6,830
4,801
1,902
1,899
2,904
4,059
6,020
19,233
10,967
10,96719,2336,0204,0592,9041,8991,9024,8016,8301,3354,0004,9682,3381,7263,0766,3627,5978,2398,82114,4216,5469,37313,675
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,400
0
0
0
18,416
10,500
10,50018,4160002,40000000000000000000
       Net Receivables 
11
53
69
222
77
92
369
3,276
1,846
17
27
624
1,013
1,168
744
420
428
331
606
689
601
1,841
1,659
1,6591,8416016896063314284207441,1681,01362427171,8463,2763699277222695311
       Other Current Assets 
0
140
879
300
403
318
66
214
60
58
63
82
175
140
94
103
195
164
257
257
665
533
1,467
1,4675336652572571641951039414017582635860214663184033008791400
   > Long-term Assets 
6,402
5,768
4,489
3,208
1,921
467
18
14
8
14
8
15
13
14
5
3
14
8
2
138
302
217
151
151217302138281435141315814814184671,9213,2084,4895,7686,402
       Property Plant Equipment 
15
52
51
47
38
21
18
14
8
14
8
15
13
14
5
3
14
8
2
138
302
217
151
15121730213828143514131581481418213847515215
       Intangible Assets 
6,388
5,716
4,438
3,161
1,883
446
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000004461,8833,1614,4385,7166,388
> Total Liabilities 
54
1,853
364
1,018
358
323
2,032
3,531
1,062
471
418
423
554
569
581
750
686
581
889
821
1,273
1,295
2,867
2,8671,2951,2738218895816867505815695544234184711,0623,5312,0323233581,0183641,85354
   > Total Current Liabilities 
54
1,853
364
1,018
358
323
1,973
3,435
1,019
456
418
423
554
569
581
750
686
581
880
799
1,046
1,161
2,812
2,8121,1611,0467998805816867505815695544234184561,0193,4351,9733233581,0183641,85354
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
2,400
113
113
79
94
94
9494791131132,400000500000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
0
0
0
0
0
0
000000000500000000000000
       Accounts payable 
0
0
0
95
44
24
26
1,027
601
29
52
14
160
117
175
215
166
104
227
108
157
331
1,023
1,0233311571082271041662151751171601452296011,02726244495000
       Other Current Liabilities 
54
50
38
924
110
299
1,947
2,409
418
427
366
409
394
402
420
535
520
477
653
691
888
829
1,789
1,7898298886916534775205354204023944093664274182,4091,947299110924385054
   > Long-term Liabilities 
0
0
0
0
0
0
59
95
43
15
0
0
0
0
0
0
0
0
9
23
228
134
55
551342282390000000015439559000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23
227
133
48
48133227230000000000000000000
       Other Liabilities 
0
0
0
0
0
0
59
95
43
15
0
0
0
0
0
0
0
0
9
0
0
1
7
710090000000015439559000000
> Total Stockholder Equity
20,034
13,482
11,618
17,133
10,864
8,793
6,017
6,335
3,928
1,344
2,018
5,266
4,647
2,087
7,092
4,577
1,853
4,221
2,810
4,531
5,728
21,141
9,976
9,97621,1415,7284,5312,8104,2211,8534,5777,0922,0874,6475,2662,0181,3443,9286,3356,0178,79310,86417,13311,61813,48220,034
   Common Stock
20,428
19,471
23,715
33,839
33,837
37,215
39,263
41,434
41,434
42,194
44,674
49,723
51,784
52,417
56,715
56,715
57,707
62,406
63,938
69,148
77,034
98,135
98,263
98,26398,13577,03469,14863,93862,40657,70756,71556,71552,41751,78449,72344,67442,19441,43441,43439,26337,21533,83733,83923,71519,47120,428
   Retained Earnings -92,289-80,909-75,098-67,037-61,129-58,184-55,853-53,098-50,584-51,291-48,278-45,823-44,022-42,208-38,783-36,133-33,996-29,161-23,698-17,432-12,823-6,715-394
   Accumulated Other Comprehensive Income 
-1
-11
726
726
726
739
750
1,034
1,276
1,358
1,366
1,366
1,141
961
961
961
-178
-184
2,420
2,420
3,791
3,916
4,002
4,0023,9163,7912,4202,420-184-1789619619611,1411,3661,3661,3581,2761,034750739726726726-11-1
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
1
737
754
775
796
827
766
1,146
1,396
1,485
1,500
1,507
1,290
1,119
1,128
1,134
178
184
-2,420
2,717
3,791
3,916
4,002
4,0023,9163,7912,717-2,4201841781,1341,1281,1191,2901,5071,5001,4851,3961,1467668277967757547371



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.